Prevail Therapeutics, Inc.

( )
PRVL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.90%74.420.0%$2402.03m
NVAXNovavax, Inc. 1.49%170.0099.2%$1226.85m
GILDGilead Sciences, Inc. 0.42%69.101.0%$551.63m
SRNESorrento Therapeutics, Inc. -1.84%13.361.8%$527.09m
AMGNAmgen, Inc. 0.03%241.551.3%$485.38m
REGNRegeneron Pharmaceuticals, Inc. -0.03%621.002.5%$436.50m
BNTXBioNTech SE 0.16%77.200.0%$395.04m
VRTXVertex Pharmaceuticals, Inc. 0.04%273.341.9%$375.17m
BIIBBiogen, Inc. 11.28%308.991.6%$348.29m
VXRTVaxart, Inc. 11.71%10.160.0%$318.72m
ILMNIllumina, Inc. -13.58%345.103.5%$277.28m
EBSEmergent BioSolutions, Inc. -5.64%126.886.4%$175.85m
IBIOiBio, Inc. 1.49%4.100.2%$171.27m
ALXNAlexion Pharmaceuticals, Inc. 0.00%103.901.9%$170.16m
SGENSeattle Genetics, Inc. -0.49%161.806.0%$165.81m

Company Profile

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.